Skip to main content Help with accessibility Skip to main navigation

CANAGLIFLOZIN, DAPAGLIFLOZIN and EMPAGLIFLOZIN as MONOTHERAPIES : a multiple prescribing statement

CCG Approval Status:

Date Added: 01 - Nov - 2017
Body System:
Green

The Pan Mersey Area Prescribing Committee recommends the prescribing of CANAGLIFLOZIN, DAPAGLIFLOZIN and EMPAGLIFLOZIN as MONOTHERAPIES as options for treating type 2 diabetes in adults in accordance with NICE TA390.